



HAL
open science

Cancer Cell Death Induced by Phosphine Gold(I) Compounds Targeting Thioredoxin Reductase

Valentina Gandin, Aristi Potamitou Fernandes, Maria Pia Rigobello, Barbara Dani, Francesca Sorrentino, Francesco Tisato, Mikael Björnstedt, Alberto Bindoli, Alberto Sturaro, Rocco Rella, et al.

► **To cite this version:**

Valentina Gandin, Aristi Potamitou Fernandes, Maria Pia Rigobello, Barbara Dani, Francesca Sorrentino, et al.. Cancer Cell Death Induced by Phosphine Gold(I) Compounds Targeting Thioredoxin Reductase. *Biochemical Pharmacology*, 2009, 79 (2), pp.90. 10.1016/j.bcp.2009.07.023 . hal-00535818

HAL Id: hal-00535818

<https://hal.science/hal-00535818v1>

Submitted on 13 Nov 2010

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Accepted Manuscript

Title: Cancer Cell Death Induced by Phosphine Gold(I)
Compounds Targeting Thioredoxin Reductase

Authors: Valentina Gandin, Aristi Potamitou Fernandes,
Maria Pia Rigobello, Barbara Dani, Francesca Sorrentino,
Francesco Tisato, Mikael Björnstedt, Alberto Bindoli, Alberto
Sturaro, Rocco Rella, Cristina Marzano



PII: S0006-2952(09)00675-3
DOI: doi:10.1016/j.bcp.2009.07.023
Reference: BCP 10279

To appear in: *BCP*

Received date: 12-6-2009
Revised date: 28-7-2009
Accepted date: 30-7-2009

Please cite this article as: Gandin V, Fernandes AP, Rigobello MP, Dani B, Sorrentino F, Tisato F, Björnstedt M, Bindoli A, Sturaro A, Rella R, Marzano C, Cancer Cell Death Induced by Phosphine Gold(I) Compounds Targeting Thioredoxin Reductase, *Biochemical Pharmacology* (2008), doi:10.1016/j.bcp.2009.07.023

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Cancer Cell Death Induced by Phosphine Gold(I) Compounds Targeting Thioredoxin Reductase

*Valentina Gandin^a; Aristi Potamitou Fernandes^b, Maria Pia Rigobello^c, Barbara Dani^c, Francesca Sorrentino^c,
Francesco Tisato^d, Mikael Björnstedt^b, Alberto Bindoli^e, Alberto Sturaro^f, Rocco Rella^f and Cristina
Marzano^{*a};*

a. Dipartimento di Scienze Farmaceutiche, Università di Padova, Via Marzolo 5, 35121 Padova, Italy

b. Karolinska Institutet, Department of Laboratory Medicine, Division of Pathology F46, Karolinska University
Hospital Huddinge, SE-141 86 Stockholm, Sweden

c. Dipartimento di Chimica Biologica, Università di Padova, Viale G. Colombo 3, 35121 Padova, Italy

d. ICIS-C.N.R., Corso Stati Uniti, 4, 35127 Padova, Italy

e. Istituto di Neuroscienze (CNR), Viale G. Colombo 3, 35121 Padova, Italy

f. IDPA-C.N.R., Corso Stati Uniti, 4, 35127 Padova, Italy

*Corresponding author: Cristina Marzano, Via Marzolo, 5 35131 Padova. Tel. +39 49 8275365 Fax. +39 49
8275366 E-mail: cristina.marzano@unipd.it

Abstract

The thioredoxin system, composed of thioredoxin reductase (TrxR), thioredoxin (Trx), and NADPH (Nicotinamide adenine dinucleotide phosphate), plays a central role in regulating cellular redox homeostasis and signaling pathways. TrxR, overexpressed in many tumor cells and contributing to drug resistance, has emerged as a new target for anticancer drugs. Gold complexes have been validated as potent TrxR inhibitors *in vitro* in the nanomolar range. In order to obtain potent and selective TrxR inhibitors, we have synthesized a series of linear, 'auranofin-like' gold(I) complexes all containing the $[\text{Au}(\text{PEt}_3)]^+$ synthon and the ligands: Cl^- , Br^- , cyanate, thiocyanate, ethylxanthate, diethyldithiocarbamate and thiourea. Phosphine gold(I) complexes efficiently inhibited cytosolic and mitochondrial TrxR at concentrations that did not affect the two related oxidoreductases glutathione reductase (GR) and glutathione peroxidase (GPx). The inhibitory effect of the redox proteins was also observed intracellularly in cancer cells pretreated with gold(I) complexes. Gold(I) compounds were found to induce antiproliferative effects towards several human cancer cells some of which endowed with cisplatin or multidrug resistance. In addition, they were able to activate caspase-3 and induce apoptosis observed as nucleosome formation and sub-G1 cell accumulation. The complexes with thiocyanate and xanthate ligands were particularly effective in inhibiting thioredoxin reductase and inducing apoptosis. Pharmacodynamic studies in human ovarian cancer cells allowed for the correlation of intracellular drug accumulation with TrxR inhibition that leads to the induction of apoptosis via the mitochondrial pathway.

Keywords: Thioredoxin reductase, phosphine metal complexes, apoptosis, drug resistance, cytotoxicity, oxidative stress

1. Introduction

Auranofin, triethylphosphine(2,3,4,6-tetra-O-acetyl- β -1-D-thiopyranosato-S)gold(I), is the first metal phosphine complex introduced into clinical practice for chrysotherapy, the treatment of rheumatoid arthritis with gold-based drugs [1], following the pioneering studies conducted with gold(I) thiolate compounds [2]. In contrast to the polymeric nature of the latter, auranofin is a discrete monomeric complex [3] composed of a tertiary phosphine and a thioglucose coordinated to the metal having bond lengths and angles [3] similar to those of typical two-coordinate, linear gold(I) compounds [4]. In this simple molecule the neutral triethylphosphine ligand was described as conferring membrane permeability while the mono-anionic tetraacetylthioglucose was reported as being displaced quite rapidly *in vivo*. Extensive multinuclear (^1H , ^{13}C and ^{31}P) NMR studies, which focused on the interaction of auranofin with serum albumin, have established that the drug appears to react at the albumin cys-34 site via a ligand-exchange reaction that displaces the sulphydryl group [5]. Both deacetylated auranofin and the parent $[\text{AuCl}(\text{PEt}_3)]$ complex form the same $[(\text{Et}_3\text{P})\text{Au}(\text{S-alb})]$ adduct by displacement of the anion. By studying reactions with auranofin instead of the unstable deacetylated form, under conditions approximating those *in vivo*, such adduct formation is of the first-order in auranofin with a rate constant of $2.9 \pm 0.2 \text{ s}^{-1}$ [6]. These data support the view that auranofin (or its deacetylated metabolite) should have a very short lifetime after entering the bloodstream where albumin is present in excessive amount (10-40 fold) compared to the gold drug [6]. To corroborate this hypothesis, Christodoulou *et al.* [7] reported a conformational change in albumin that accompanies gold binding to cys-34. Taken together the above studies indicate that the pharmacokinetic of auranofin appears to be markedly affected by the lability of the metal-thioglucose bond, thereby suggesting that subtle modification of this interaction could produce changes in the biological profile of the drug.

Auranofin was shown to possess *in vivo* antitumor activity against P388 murine leukemia and *in vitro* cytotoxic potency against both B16 melanoma and P388 leukemia cells for two decades [8]. However, very recently, additional *in vitro* studies indicated that auranofin is able to overcome cisplatin resistance in human

1 ovarian cancer cells [9], confirming the earlier assumption that a mechanism of action different from the
2
3 recognized DNA damage induced by cisplatin could underlie the cytotoxic activity of phosphine Au(I) drugs. In
4
5 particular, it was found that auranofin, acting as a potent inhibitor of thioredoxin reductase, causes an alteration
6
7 of the redox state of the cell leading to an increased production of hydrogen peroxide and oxidation of the
8
9 components of the thioredoxin (Trx) system, therefore creating the conditions for enhanced apoptosis [9].
10
11

12
13
14
15 Among TrxR inhibitors, gold compounds are very effective, acting at nanomolar levels, probably due to the
16
17 high affinity of gold towards chalcogenides (group 16 donors including S, Se and Te) which renders the
18
19 nucleophilic selenolate of reduced TrxR the prime target site of modification by this metal. Hence, as pointed
20
21 out above, the linear structure of auranofin and especially the lability of the thioglucose group appears to play a
22
23 peculiar role both in the pharmacokinetic profile and in the cytotoxic effect of this molecule. It was also shown
24
25 that phosphinegold(I) thiolates were more cytotoxic than gold(I) thiolates, and that phosphinegold(I) thiolates
26
27 had more promising cytotoxicity profiles than their chloride analogues, indicating the importance of both the
28
29 phosphine and the thiolate ligand for cytotoxic activity. We have consequently synthesized a series of
30
31 'auranofin-like' gold(I) complexes maintaining intact the $[\text{Au}(\text{PET}_3)]^+$ moiety and replacing the thioglucose
32
33 anion with other mono-dentate ligands which have binding potential to gold(I). This series comprises of
34
35 common gold(I) precursors such as $[\text{AuCl}(\text{PET}_3)]$ (**1**) and $[\text{AuBr}(\text{PET}_3)]$ (**2**) along with complexes containing
36
37 mainly sulfur donor atoms having different nucleophilicity such as diethyldithiocarbamate (dedc), xanthate
38
39 (xant), thiocyanate (SCN), thiourea (tu), and cyanate (CN) (see Scheme 1). The choice of these co-ligands was
40
41 based on the rationale to optimize or customize TrxR inhibition by changing the thioglucose residue of
42
43 auranofin, and on the availability of relatively simple synthetic procedures already reported in the literature for
44
45 the preparation of linear phosphine gold(I) complexes. Thiocyanate and cyanide represent gold ligands involved
46
47 in human metabolism of auranofin-like gold(I) complexes whose major pathway implicates myeloperoxidase
48
49 [10]. Dithiocarbamates (DTCs) and xanthate are well known heavy-metal chelating agents which possess
50
51 various biological activities [11]. Due to their lipophilic character, they may allow the formation of bioactive
52
53 metal complexes with great tendency to cross the cell membrane by passive diffusion. Certain phosphine gold(I)
54
55
56
57
58
59
60
61
62
63
64
65

1 xanthate and dithiocarbamate compounds have proved to possess antiarthritic and *in vitro* antitumor activities
2
3 [12]. Moreover, some gold(III)-DTC complexes have recently demonstrated an outstanding potential as
4
5 anticancer agents able to overcome cisplatin resistance [13].
6
7
8
9

10 In the current study we have assessed the antitumor properties of these gold(I) compounds towards a wide
11
12 panel of human cancer cell lines also including cisplatin and multidrug resistant (MDR) phenotypes. Gold(I)
13
14 complexes were evaluated for their capacity to inhibit cytosolic and/or mitochondrial isoforms of TrxR, both *in*
15
16 *vitro* (in a cell-free system) and in human ovarian cancer cells. The inactivation of the closely related enzymes
17
18 glutathione reductase (GR) and glutathione peroxidase (GPx) was also examined with the aim of assessing
19
20 gold(I) complex selectivity. Finally, reactive oxygen species (ROS) production and triggering of apoptosis in
21
22 treated cancer cells, consequent to cellular TrxR targeting, have been investigated.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

2. Material and methods

2.1. Synthesis

All reagents and $[\text{AuCl}(\text{PEt}_3)]$, (**1**), were purchased from Aldrich (St. Louis, MO, USA) and used without further purification. Phosphine gold(I) complexes were prepared in accordance with published procedures.

2.1.1. $[\text{AuBr}(\text{PEt}_3)]$, (**2**), was prepared as described by El-Etri *et al.* [14] ^1H NMR (CDCl_3 , δ) 1.21 (dt, $\text{P}(\text{CH}_2\text{CH}_3)_3$, 9H; $^3J_{\text{HH}} = 7.6$ Hz, $^3J_{\text{HP}} = 18.9$ Hz), 1.84 (dq, $\text{P}(\text{CH}_2\text{CH}_3)_3$, 6H; $^3J_{\text{HH}} = 7.6$ Hz, $^3J_{\text{HP}} = 18.9$ Hz). $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , δ) 11.78 (s, $\text{P}(\text{CH}_2\text{CH}_3)_3$), 21.02 (d, $\text{P}(\text{CH}_2\text{CH}_3)_3$); $^1J_{\text{CP}} = 35.9$ Hz). $^{31}\text{P}\{^1\text{H}\}$ NMR (CDCl_3 , δ) 35.18 (s).

2.1.2. $[\text{Au}(\text{CN})(\text{PEt}_3)]$, (**3**), was prepared as described by El-Etri *et al.* [14] ^1H NMR (CDCl_3 , δ) 1.21 (dt, $\text{P}(\text{CH}_2\text{CH}_3)_3$, 9H; $^3J_{\text{HH}} = 7.6$ Hz, $^3J_{\text{HP}} = 18.6$ Hz), 1.84 (m, $\text{P}(\text{CH}_2\text{CH}_3)_3$, 6H). $^{31}\text{P}\{^1\text{H}\}$ NMR (CDCl_3 , δ) 36.81 (s).

2.1.3. $[\text{Au}(\text{SCN})(\text{PEt}_3)]$, (**4**), was prepared as described by El-Etri *et al.* [14] ^1H NMR (CDCl_3 , δ) 1.23 (dt, $\text{P}(\text{CH}_2\text{CH}_3)_3$, 9H; $^3J_{\text{HH}} = 7.6$ Hz, $^3J_{\text{HP}} = 18.6$ Hz), 1.89 (m, $\text{P}(\text{CH}_2\text{CH}_3)_3$, 6H), $^{31}\text{P}\{^1\text{H}\}$ NMR (CDCl_3 , δ) 37.23 (s).

2.1.4. $[\text{Au}(\text{dedc})(\text{PEt}_3)]$, (**5**) was prepared according to de Vos *et al.* [11] ^1H NMR (CDCl_3 , δ) 1.19 (t, $>\text{CN}(\text{CH}_2\text{CH}_3)_2$, 6H; $^3J_{\text{HH}} = 7.6$ Hz), 1.21 (dt, $\text{P}(\text{CH}_2\text{CH}_3)_3$, 9H; $^3J_{\text{HH}} = 7.6$ Hz, $^3J_{\text{HP}} = 18.9$ Hz), 1.83 (m, $\text{P}(\text{CH}_2\text{CH}_3)_3$, 6H), 3.89 (q, $>\text{N}(\text{CH}_2\text{CH}_3)_2$, 4H; $^3J_{\text{HH}} = 7.6$ Hz). $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , δ) 11.72 (s, $\text{P}(\text{CH}_2\text{CH}_3)_3$), 15.00 (s, $>\text{N}(\text{CH}_2\text{CH}_3)_2$), 21.33 (d, $\text{P}(\text{CH}_2\text{CH}_3)_3$); $^1J_{\text{CP}} = 33.6$ Hz). $^{31}\text{P}\{^1\text{H}\}$ NMR (CDCl_3 , δ) 34.76 (s).

1
2
3 2.1.5. [Au(xant)(PEt₃)], (**6**) was prepared according to de Vos *et al.* [11] ¹H NMR (CDCl₃, δ), 1.25 (dt,
4
5 P(CH₂CH₃)₃, 9H; ³J_{HH} = 7.6 Hz, ³J_{HP} = 18.9 Hz), 1.39 (t, >COCH₂CH₃, 3H; ³J_{HH} = 7.1 Hz) 1.84 (m,
6
7 P(CH₂CH₃)₃, 6H), 4.50 (q, >COCH₂CH₃, 2H; ³J_{HH} = 7.1 Hz). ¹³C{¹H} NMR (CDCl₃, δ) 11.84 (s, P(CH₂CH₃)₃),
8
9 16.91 (s, >COCH₂CH₃), 21.02 (d, P(CH₂CH₃)₃); ¹J_{CP} = 33.9 Hz). ³¹P{¹H} NMR (CDCl₃, δ) 36.65 (s).
10
11
12
13
14

15 2.1.6. [Au(tu)(PEt₃)]Cl, (**7**), was synthesised by the method used by Coates *et al.* [15] to prepare the
16
17 bromide analog. ¹H NMR (*dms**o*-d₆, δ) 1.09 (dt, P(CH₂CH₃)₃, 9H; ³J_{HH} = 7.6 Hz, ³J_{HP} = 19.2 Hz), 1.90 (m,
18
19 P(CH₂CH₃)₃, 6H), 7.27 (broad s, 4H; SC(NH₂)₂). ³¹P{¹H} NMR (CDCl₃, δ) 36.31 (s).
20
21
22
23
24

25 2.1.7. [Au(2,3,4,6-tetra-O-acetyl-β-1-D-thiopyranosato-S)(PEt₃)], (**8**) Auranofin was obtained from Alexis
26
27 Biochemicals (Lausen, Switzerland) or it was prepared according to Sutton *et al.* [16] ¹H NMR (CDCl₃, δ) 1.22
28
29 (dt, P(CH₂CH₃)₃, 9H; ³J_{HH} = 7.6 Hz, ³J_{HP} = 18.4 Hz), 1.85 (m, P(CH₂CH₃)₃, 6H), 1.98, 2.01, 2.05 and 2.08 (four
30
31 s, -OCH₃, 3+3+3+3 H), 3.71 (bs, 1H), 4.09 (d, 1H), 4.24 (dd, 1H), 4.99 (m, 1H), 5.12 (m, 3H) (methine and
32
33 s, -OCH₃, 3+3+3+3 H), 3.71 (bs, 1H), 4.09 (d, 1H), 4.24 (dd, 1H), 4.99 (m, 1H), 5.12 (m, 3H) (methine and
34
35 methylene H of the thioglucopyranosato backbone). ³¹P{¹H} NMR (CDCl₃, δ) 38.06 (s).
36
37
38
39

40 2.2. Experiments with human cells

41
42
43
44
45 Cisplatin, auranofin and the synthesized complexes, along with the corresponding uncoordinated ligands,
46
47 were dissolved in DMSO, just before the experiment. Calculated amounts of drug solution were added to the
48
49 growth medium to a final solvent concentration of 0.5%, which had no discernible effect on cell killing. MTT
50
51 (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) and cisplatin were obtained from Sigma-
52
53 Aldrich, St. Louis, MO, USA.
54
55
56
57
58

59 2.2.1. Cell cultures. Human lung (A549), breast (MCF-7), colon (HCT-15) and cervix (HeLa) carcinoma cell
60
61 lines along with melanoma (A375) and promyelocytic leukemia (HL60) cell lines were obtained by ATCC,
62
63
64
65

1 Rockville, MD. 2008 cell line, its cisplatin-resistant (C13*) and -revertant (RH4) variants, , are human ovarian
2
3 cancer cells kindly provided by Prof. G. Marverti (Dept. of Biomedical Science of Modena University, Italy).
4
5 A431 and A431-Pt are sensitive and resistant human cervix carcinoma cells, respectively; they were kindly
6
7 provided by Prof. F. Zunino (Division of Experimental Oncology B, Istituto Nazionale dei Tumori, Milan,
8
9 Italy). LoVo human colon-carcinoma cell line and its derivative multidrug-resistant subline (LoVo MDR) were
10
11 kindly provided by Prof. F. Majone (Department of Biology of Padova University, Italy). The human parental
12
13 lung carcinoma U1285 cell line was obtained from ATCC (American Type Culture Collection) whereas its
14
15 doxorubicin-resistant subline U1285dox, was selected to tolerate 1.6 μM doxorubicin as previously described
16
17 [17]. Cell lines were maintained in the logarithmic phase at 37°C in a 5% carbon dioxide atmosphere using the
18
19 following culture media containing 10% foetal calf serum (Euroclone, Milan, Italy), antibiotics (50 units·mL⁻¹
20
21 penicillin and 50 $\mu\text{g}\cdot\text{mL}^{-1}$ streptomycin) and 2mM l-glutamine : i) RPMI-1640 medium (Euroclone) with 25
22
23 mM HEPES buffer for HL60, MCF-7, HCT-15, 2008, C13*, RH4, A431, A431-Pt, U1285 and U1285dox cells;
24
25 ii) F-12 HAM'S (Sigma-Aldrich) for HeLa, LoVo and LoVo MDR cells; iii) D-MEM medium (Euroclone), for
26
27 A549 and A375 cells. LoVo MDR culture medium also contained 0.1 $\mu\text{g}\cdot\text{mL}^{-1}$ doxorubicin.
28
29
30
31
32
33
34
35
36
37

38 2.2.2. Cytotoxicity assay. The growth inhibitory effect towards tumor cell lines was evaluated by means of
39
40 MTT (tetrazolium salt reduction) assay [18]. Briefly, 3-8·10³ cells/well, dependent upon the growth
41
42 characteristics of the cell line, were seeded in 96-well microplates in growth medium (100 μL) and then
43
44 incubated at 37°C in a 5% carbon dioxide atmosphere. After 24 h, the medium was removed and replaced with a
45
46 fresh one containing the compound to be studied at the appropriate concentration. Triplicate cultures were
47
48 established for each treatment. After 48 or 72 h, each well was treated with 10 μL of a 5 mg·mL⁻¹ MTT (3-(4,5-
49
50 dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) saline solution, and after 5 h of incubation, 100 μL of a
51
52 sodium dodecylsulfate (SDS) solution in HCl 0.01 M was added. After overnight incubation, the inhibition of
53
54 cell growth induced by the tested complexes was detected by measuring the absorbance of each well at 570 nm
55
56 using a Bio-Rad 680 microplate reader. Mean absorbance for each drug dose was expressed as a percentage of
57
58
59
60
61
62
63
64
65

1 the control untreated well absorbance and plotted vs drug concentration. IC₅₀ values represent the drug
2
3 concentrations that reduced the mean absorbance at 570 nm to 50% of those in the untreated control wells.
4
5
6
7

8 2.2.3. Cellular uptake. $2 \cdot 10^6$ 2008 cells were seeded in 75 cm² flasks in growth medium (20 mL). After 24 h,
9
10 the medium was replaced and the cells incubated for 6, 12 and 18 h in the presence of tested gold complexes.
11
12 Cell monolayers were washed twice with cold PBS and harvested. Samples were subjected to three
13 freezing/thawing cycles at -80 °C, and then vigorously vortexed. Aliquots were removed for the determination
14
15 of protein content by the Lowry assay [19]. The samples were added of 5 mL 65% nitric acid and transferred
16
17 into a microwave teflon vessel. Subsequently, samples were digested using a speed wave MWS-3 Berghof
18
19 instrument (Eningen, Germany). After cooling, each mineralized sample was poured into a plastic vial and
20
21 diluted to 10 mL with ultra pure water. The determinations of gold were performed by using an axial ICP-OES
22
23 Liberty, Series II, Varian (Palo Alto, CA, USA), at the wavelength 242.795 nm. The calibration curve was
24
25 obtained using known concentrations of standard solutions purchased by Sigma-Aldrich.
26
27
28
29
30
31
32
33
34

35 2.3. Enzyme inhibition

36
37
38
39

40 2.3.1. Isolation and purification of thioredoxin reductases from rat liver cytosol and mitochondria. Highly
41
42 purified cytosolic thioredoxin reductase (TrxR1) was prepared according to Luthman and Holmgren [20]
43
44 starting from rat liver cytosol obtained after centrifugation of the liver homogenate at 45,000g for 1 h.
45
46 Mitochondrial thioredoxin reductase (TrxR2) was purified from liver mitochondria following the procedure of
47
48 Rigobello *et al.* [21]. After affinity chromatography (2', 5'-ADP-sepharose), the enzymes were further purified
49
50 by chromatography through a ω -aminohexyl-sepharose 4B column. Briefly, the fractions obtained after the
51
52 affinity chromatography step were concentrated by ultrafiltration and than applied on a ω -aminohexyl-sepharose
53
54 4B column equilibrated with 50 mM Tris-HCl buffer (pH 7.5) and the enzymatic fraction was eluted with a
55
56 linear gradient of NaCl (from 0.0 to 0.8 M). The enzyme showed a unique band on SDS-PAGE.
57
58
59
60
61
62
63
64
65

1 2.3.2. *In vitro* TrxR1 and TrxR2 inhibition. The assay was performed in 0.2 M Na, K-phosphate buffer (pH
2
3 7.4) containing 2 mM EDTA, 0.25 mM NADPH and about 0.5-2 μ g of TrxR protein. The reaction was initiated
4
5 by the addition of 3 mM DTNB (5,5'-dithiobis (2-nitrobenzoic acid)) to both sample and reference and the
6
7 increase of absorbance was monitored at 412 nm over 5 min at 25 °C. Enzyme activity was calculated taking
8
9 into account that 1 mole of NADPH yields 2 moles of CNTP anion (reduced DTNB).
10
11

12
13
14
15 2.3.3. *In vitro* GR inhibition. Glutathione reductase activity was estimated at 25 °C in 0.1 M Tris/HCl (pH
16
17 8.1) containing 0.2 mM NADPH. Reactions were started by the addition of 1 mM GSSG and followed
18
19 spectrophotometrically at 340 nm.
20
21

22
23
24
25 2.3.4. *In vitro* GPx inhibition. Glutathione peroxidase activity was estimated at 25 °C in 50 mM Hepes/Tris
26
27 (pH 7.0) and EDTA 3 mM, 0.3 mM NADPH, 5 mM GSH and 0.25 mM tert-butyl hydroperoxide according to
28
29 Little *et al.* [22].
30
31

32
33
34
35 2.3.5. Inhibition of redox enzymes by gold(I) complexes in cells. 2008 cells were grown in 75 cm² flasks at
36
37 confluence and treated with gold complexes at concentrations corresponding to IC₅₀ values for 18 h. At the end
38
39 of incubation time, cells were collected, washed with PBS and centrifuged. Each sample was then lysed with
40
41 RIPA buffer modified as follows: 150 mM NaCl, 50 mM Tris-HCl, 1% Triton X-100, 1 % SDS, 1% DOC, 1
42
43 mM NaF, 1 mM EDTA, and immediately before use, an anti-protease cocktail (Roche, Basel, Switzerland)
44
45 containing PMSF was added supplemented with protease inhibitors. Samples were tested for thioredoxin
46
47 reductase (0.080 mg proteins), glutathione reductase (0.080 mg proteins) and glutathione peroxidase (0.5mg
48
49 proteins) activities as above described.
50
51
52
53

54 55 56 57 **2.4 Apoptosis studies** 58 59 60 61 62 63 64 65

1 2.4.1. Caspase-3 activation. Caspase-3 activity was detected by using the ApoAlert Caspase-3 Fluorescent
2
3 Assay Kit (Clontech, Mountain View, CA, USA) according to the manufacturer's recommended procedures.
4
5 2008 cells ($1 \cdot 10^6$) were collected after 12 h of incubation in the presence of tested compounds (at concentrations
6
7 corresponding to IC_{50} values) and lysed on ice in 50 μ L of lysis buffer for 10 min, then treated with 50 μ L of
8
9 reaction buffer containing dithiothreitol (DTT) and 5 μ L of caspase-3 substrate solution (Asp-Glu-Val-Asp-7-
10
11 amino-4-trifluoromethyl-coumarin [DEVD-AFC], Clontech). The fluorescence was determined with a Perkin-
12
13 Elmer 550 spectrofluorometer (excitation 440 nm, emission 505 nm). The caspase-3 activity was expressed as
14
15 the increase of the AFC-emitted fluorescence.
16
17
18
19
20
21
22

23 2.4.2. Nuclear DNA fragmentation. 2008 or C13* cells (10^4 per well) were treated in a 96-well plate at 37°C
24
25 for 24 h with IC_{50} concentration of tested compounds, 1.5 μ M auranofin and 25 μ M cisplatin. Afterwards, the
26
27 plate was centrifuged for 10 min, the supernatant removed, and the pellet treated according to the
28
29 manufacturer's instructions of the ELISA^{plus} cell death detection kit (Roche). The extent of nuclear
30
31 fragmentation was measured in a plate reader following absorbance at 405 minus 492 nm.
32
33
34
35
36
37

38 2.4.3. DAPI and Hoechst 33342 staining. 2008 cells were seeded into 8-well tissue-culture slides (BD
39
40 Falcon, Bedford, MA, USA) at $5 \cdot 10^4$ cells/well (0.8 cm^2). After 24 h, cells were washed twice with PBS and
41
42 following 24 h of treatment with IC_{50} concentration of tested complexes cells were fixed in 4% freshly prepared,
43
44 ice-cold paraformaldehyde, postfixed in ethanol and air-dried. Slides were then stained for 5 min with 5 μ g/mL
45
46 4,6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich,) or 1 mg/mL Hoechst (Sigma-Aldrich,) in PBS before
47
48 being examined by fluorescence microscopy (Olympus BX41, Cell F software, Olympus, Munster, Germany).
49
50
51
52
53
54

55 2.5. Reactive oxygen species (ROS) production

56
57
58
59

60 The production of ROS was measured in 2008 cells (10^4 per well) grown for 24 h in a 96-well plate in RPMI
61
62 1640 without phenol red. Cells were then washed in PBS/10 mM glucose and loaded with 10 μ M 2',7'-
63
64
65

1 dichlorodihydrofluorescein diacetate (H₂-DCFDA) (Molecular Probes-Invitrogen, Eugene, OR) for 20 min, in
2
3 the dark. Afterwards, the cells were washed with the same medium and incubated with IC₅₀ concentration of
4
5 tested compounds. Fluorescence increase of DCFDA was estimated utilizing the wavelengths of 485 nm
6
7 (excitation) and 527 nm (emission) in a Fluoroskan Ascent FL (Labsystem, Finland) plate reader. Antimycin (3
8
9 μM, Sigma), a potent inhibitor of Complex III in the electron transport chain, was used as positive control.
10

15 2.6. Flow cytometric analysis

16
17
18
19
20 Drug-induced cell cycle effects and DNA fragmentation were analysed by flow cytometry after DNA
21
22 staining with propidium iodide (PI) according to Nicoletti *et al.* [23]. Briefly, 2008 cells (5·10⁵ cells) were
23
24 exposed for 1-24 h to tested compound concentrations corresponding to IC₅₀ values. PI solution (1 mL)
25
26 containing 50 μg/mL of PI, 0.1% m/v of Triton X-100 and 0.01% m/v of sodium citrate, was added to cells and
27
28 then incubated for 25 minutes at 4°C in the dark. Induced cell death was determined as percentage of
29
30 hypodiploid nuclei counted over the total cell population measured by FACScalibur flow cytometer (Becton–
31
32 Dickinson, CA, USA) using a 550-600 nm filter. Analysis was performed by Cell Quest software (Becton–
33
34 Dickinson).
35
36
37
38
39
40
41

42 2.7. Statistical analysis

43
44
45
46
47 All the values are the means ± SD of not less than five measurements. Multiple comparisons were made by
48
49 one-way analysis of variance followed by Tukey-Kramer multiple comparison test or ANOVA test
50
51
52 (**p<0.001; *p<0.01; * p<0.05).
53
54
55
56
57
58
59
60
61
62
63
64
65

3. Results

3.1. Synthesis of phosphine gold(I) complexes

Phosphine gold(I) complexes were prepared according to the literature procedures as outlined in Figure 1. The commercially available complex $[\text{AuCl}(\text{PEt}_3)]$ (**1**) was utilized as the precursor of gold(I) compounds which were obtained by replacing directly, or via the aquo derivative, the labile chloride group. By reactions with the pertinent salt (NaBr, KCN and KSCN) in aqueous solutions, the aquo intermediate species gave the corresponding neutral bromo, (**2**) cyano (**3**) and thiocyanato (**4**) complexes [10], respectively. Direct mixing of $[\text{AuCl}(\text{PEt}_3)]$ and sodium diethyldithiocarbamate (Nadec) or potassium xanthate (Kxant) in ethanol/water solutions afforded neutral $[\text{Au}(\text{dedc})(\text{PEt}_3)]$ (**5**) and $[\text{Au}(\text{xant})(\text{PEt}_3)]$ (**6**) complexes [11], whereas mixing with thiourea (tu) gave the monocationic complex $[\text{Au}(\text{tu})(\text{PEt}_3)][\text{Cl}]$ (**7**) [15]. The physico-chemical data of these compounds correlate well with the analytical data of the corresponding complexes reported in the literature.

For comparison purposes, Table 1 shows selected X-ray parameters and ^{31}P NMR chemical shifts of the triethylphosphine gold(I) compounds utilised in our study. X-ray data taken from the literature confirm that the molecular structure of all of these complexes adopts a near-linear arrangement (P-Au-X angle in the narrow $173.6 - 178.7^\circ$ window). The Au-P distance is a little affected by the nature of the *trans*-coordinated atom, being restricted in the 2.245-2.265 Å range in the case of *trans*-S donors, and slightly lengthened at 2.288 Å by the cyano group [24]. On the other side, the Au-S distance lengthens from 2.293 Å in Auranofin [24] to 2.337 Å in the dedc derivative [25], suggesting that the metal S-thioglucose bond may be considered stronger than the metal S-dithiocarbamate bond. The analysis of NMR data establishes that coordination of PEt_3 to Au(I) induces a significant downfield shift of the ^{31}P signal from -17.8 ppm in uncoordinated PEt_3 to $\text{ca. } 35 \pm 3$ ppm in the gold complexes pointing toward a strong metal phosphine interaction. The larger downfield shift is observed for Auranofin, suggesting that this complex has the strongest metal-P bond in the series.

1
2
3
4 We have also checked the stability of these gold(I) complexes in the reconstituting solvent DMSO by means
5
6 of NMR. All of them were found to be stable for the time necessary before addition to the growth medium.
7
8 However, the cyano and xant derivatives appears less stable. As previously reported [26], the cyano complex
9
10 undergoes a disproportionation reaction as specified in Eq(I) below
11
12



21 3.2. Cytotoxicity Studies

$$22$$

$$23$$

$$24$$

25 Gold(I) complexes and the corresponding uncoordinated ligands were examined for their cytotoxic
26
27 properties against a panel of human tumor cell lines including lung (A549), colon (HCT-15), breast (MCF-7)
28
29 and cervical (HeLa) cancers along with leukemia (HL60) and melanoma (A375). Under the same experimental
30
31 conditions, cisplatin and auranofin were also evaluated, the former as the most widely used anticancer
32
33 metallodrug and the latter as the reference phosphine gold(I) compound. IC₅₀ values, calculated from the dose-
34
35 survival curves obtained after 72 h of drug treatment from the MTT test, are shown in Table 2. Uncoordinated
36
37 ligands proved to be quite ineffective against all tumor cell lines (data not shown). Although the
38
39 [Au(tu)(PEt₃)]Cl complex showed a cytotoxic potency higher than that of cisplatin, it proved to be roughly 5-
40
41 times less effective than auranofin in decreasing cell viability over 6 cancer cell types. [Au(dedc)(PEt₃)],
42
43 [AuCl(PEt₃)] and [AuBr(PEt₃)] complexes showed a cytotoxic activity in the sub-micromolar range against all
44
45 cancer cell lines, with IC₅₀ average values from about 15- to 20-fold lower than those obtained with cisplatin
46
47 and comparable with those exhibited by the phosphine gold(I) reference drug. The most effective compounds
48
49 were [Au(xant)(PEt₃)], [Au(CN)(PEt₃)] and [Au(SCN)(PEt₃)]. Xanthogenate, cyanate and thiocyanate gold(I)
50
51 complexes showed IC₅₀ average values of about 80 and 2 times lower than that of cisplatin and auranofin,
52
53 respectively. Interestingly, they appeared efficient against human non-small lung A549 and colon HCT-15
54
55 cancer cells, notoriously poorly sensitive to cisplatin, thus reflecting their ability to overcome intrinsic cisplatin
56
57
58
59
60
61
62
63
64
65

1 resistance. Moreover, classical clonogenic assays were performed in 2008 human ovarian cancer cells exposed
2
3 to tested compounds and results were found very consistent with data obtained with MTT test (data not shown).
4

5
6 The encouraging results obtained against the in-house panel of cell lines prompted us to test the cytotoxic
7
8 activity of these gold(I) complexes onto three additional cell line pairs, two of which (2008/C13* human
9
10 ovarian cancer cells and A431/A431-Pt human cervix carcinoma cells) had been *in vitro* selected for their
11
12 resistance to cisplatin and two (U1285/U1285dox human lung cancer cells and LoVo/LoVoMDR human colon
13
14 adenocarcinoma cells) selected for their resistance to doxorubicin, thus retaining the MDR phenotype. Although
15
16 cisplatin resistance is multifactorial, the main molecular mechanisms involved in C13* and A431-Pt cell
17
18 resistance have almost been defined. In particular, in human ovarian cancer C13* cells, resistance is correlated
19
20 to reduced cellular drug uptake, high cellular glutathione and thioredoxin reductase levels [9], and enhanced
21
22 repair of DNA damage [27]. In human squamous cervical carcinoma A431-Pt cells, resistance is due to defect in
23
24 drug uptake and to decreased levels of proteins involved in DNA mismatch repair (MSH2), causing an increased
25
26 tolerance to cisplatin-induced DNA damage [28]. Cytotoxicity of tested compounds in cisplatin sensitive and
27
28 resistant cells was assessed after a 48-h drug exposure by the MTT test (Table 3). Cross-resistance profiles were
29
30 evaluated by means of the resistance factor (RF), which is defined as the ratio between IC₅₀ values calculated
31
32 for the resistant cells and those arising from the sensitive ones. All the tested gold(I) complexes, as well as
33
34 auranofin, exhibited a different cross-resistance profile than that of cisplatin. RF values calculated for all gold(I)
35
36 complexes were about 2 and 10 times lower than those calculated for cisplatin against human cervix and ovarian
37
38 cancer cell line pairs, respectively. These results attesting their ability to overcome resistance in both cisplatin
39
40 phenotypes (C13* and A431/Pt) strongly support the hypothesis of a different pathway of action of these gold(I)
41
42 complexes from that of cisplatin. Table 3 also reports data obtained in RH4 cisplatin-revertant cells, a cisplatin-
43
44 sensitive cell line obtained from C13* subline after reverting cisplatin resistance [29]. RH4 revertant cells have
45
46 been isolated from C13* cells by selection with the lipophilic cation rhodamine123. The RH4 cells lost a
47
48 substantial portion of their cisplatin resistance, being only 2- to 3-fold resistant to cisplatin. Despite this major
49
50 loss of resistance, they retained a number of the phenotypic features related to cisplatin resistance, observed in
51
52 C13* cells [29]. As a whole, against RH4 cells, the behavior of all gold complexes was comparable to that
53
54
55
56
57
58
59
60
61
62
63
64
65

1 elicited in the cisplatin sensitive 2008 cell line, even if Au(SCN)PEt₃ emerged as the most efficient in inhibiting
2
3 RH4 cell growth.
4

5
6
7
8 Acquired multidrug resistance (MDR), whereby cells become refractory to multiple drugs, poses a very
9
10 important challenge to the success of anticancer chemotherapy. The resistance of U1285dox cells to
11
12 doxorubicin, a drug belonging to the MDR spectrum, is an atypical multidrug-resistance characterised by the
13
14 absence of the P-glycoprotein (P-gp) overexpression as well as by the overexpression of MRP1 [30]. Recently,
15
16 in U1285dox cells, the basal level of active TrxR has been found significantly higher (1.5-fold) than in the drug
17
18 sensitive U1285 cells [17]. On the contrary, in LoVo/MDR cells, resistance to doxorubicin is associated with an
19
20 overexpression of the multispecific drug transporters, such as the 170 kDa P-glycoprotein [31]. Cytotoxicity of
21
22 tested compounds in wild-type and MDR strain cells was assessed after a 48 h drug exposure by the MTT test
23
24 (Table 4). The calculation of an RF average value from about 35 to 88 times lower than that obtained with
25
26 doxorubicin, in U1285dox and LoVo/MDR, respectively, clearly suggests that gold(I) complexes are not
27
28 potential MDR substrates. [Au(xant)(PEt₃)], [Au(CN)(PEt₃)] and [Au(SCN)(PEt₃)] were particularly powerful
29
30 in decreasing viability of both resistant phenotypes.
31
32
33
34
35
36
37
38
39

40 **3.3. Inhibition of purified thioredoxin reductase, glutathione peroxidase and glutathione reductase**

41
42
43
44 The inhibitory effects of gold(I) complexes toward cytosolic or mitochondrial isoforms of isolated rat TrxR
45
46 were measured according to the current procedures [20]. Gold(I) complexes were tested at increasing
47
48 concentrations and IC₅₀ values were calculated from the dose-effect curves (Table 5). The cytosolic isoform
49
50 appeared markedly inhibited by all gold(I) derivatives at nanomolar concentrations. Some complexes such as
51
52 [Au(xant)(PEt₃)] and [Au(dedc)(PEt₃)] exhibited IC₅₀ values lower than that determined after auranofin
53
54 treatment whereas [Au(CN)(PEt₃)] and [Au(tu)(PEt₃)] [Cl] showed an inhibitory potency similar to that observed
55
56 for auranofin. The IC₅₀ values calculated for [AuCl(PEt₃)], [Au(SCN)(PEt₃)] and [AuBr(PEt₃)] appeared slightly
57
58 lower than those determined for auranofin.
59
60
61
62
63
64
65

1
2
3 Mitochondrial thioredoxin reductase appeared less sensitive to the inhibitory effect promoted by the tested
4
5
6 complexes and higher concentrations were required for a reduction of 50% of TrxR2 activity (Table 5).
7
8 Moreover, the IC_{50} values obtained with all gold(I) derivatives were higher than that obtained with auranofin,
9
10 excluding those calculated for $[Au(xant)(PEt_3)]$ and $[Au(dcdc)(PEt_3)]$. The difference in sensitivity to gold
11
12 derivatives is a common feature of the two thioredoxin reductases and possibly depends on the different
13
14 sequence of the two isoforms and the greater acidity of cytosolic thioredoxin reductase [32].
15
16

17
18 With the aim of attesting the selectivity of phosphine gold(I) compounds toward thioredoxin reductase
19
20 isoenzymes, we had also performed glutathione reductase and peroxidase inhibition tests. IC_{50} values were
21
22 calculated from the dose-effect curves obtained testing gold(I) complexes within the 1-100 μM range (Table 5).
23
24
25 $[Au(tu)(PEt_3)][Cl]$ appeared the most active in reducing Gpx activity, while $[Au(SCN)(PEt_3)]$ markedly
26
27 inhibited glutathione reductase. However, glutathione reductase and glutathione peroxidase were affected by all
28
29 complexes in the micromolar range of concentration, *i. e.* three orders of magnitude higher than those required
30
31 for TrxR inhibition. These results clearly suggest that these complexes preferentially inhibit thioredoxin
32
33 reductase over the other redox enzymes.
34
35
36
37
38
39

40 **3.4. Effects of gold(I) complexes on redox enzymes in human ovarian cancer cells**

41
42
43
44

45 TrxR inhibition was also evaluated in 2008 cells treated for 18 h with IC_{50} concentrations of gold(I)
46
47 complexes. As illustrated in Fig. 2A, all tested complexes showed IC_{50} values comparable with that obtained
48
49 with auranofin; $[Au(CN)(PEt_3)]$, $[Au(SCN)(PEt_3)]$ and $[AuBr(PEt_3)]$ were the most active derivatives, being
50
51 able to decrease cellular TrxR activity by approximately 90, 92 and 94% with respect to untreated cells.
52
53

54 Similarly to the isolated enzymes, also in cultured cells glutathione reductase and peroxidase were inhibited
55
56 by gold(I) complexes, although far less intensely than thioredoxin reductase. Interestingly, $[Au(tu)(PEt_3)][Cl]$, a
57
58 charged gold(I) compound, noticeably inhibited isolated glutathione peroxidase, but it was far less effective in
59
60
61
62
63
64
65

1 inhibiting the same enzyme in 2008 cancer cells in line with its scarce permeability to plasmalemma, as shown
2
3 in Fig. 3.
4

5 6 7 8 **3.5. Cellular uptake** 9

10
11
12
13 In our previous studies we had highlighted the relationship between auranofin cytotoxicity and cellular
14
15 accumulation [9]. Cellular uptake of phosphine gold(I) complexes was quantified, by means of ICP analysis, in
16
17 2008 cells after a continuous treatment with IC₅₀ concentrations lasting 6, 12 and 18 h. Intracellular
18
19 accumulation was time-dependent and reached the highest levels after 18 h exposure. Most probably, for longer
20
21 accumulations the detection may be affected by the strong cytotoxicity induced by gold derivatives. As seen in Fig.
22
23 3, which reports the results after 18 h treatment, [Au(xant)(PEt₃)], [Au(dedc)(PEt₃)], [Au(CN)(PEt₃)] and
24
25 [Au(SCN)(PEt₃)] entered cancer cells with a similar efficiency to auranofin, whereas [AuBr(PEt₃)] and
26
27 [AuCl(PEt₃)] cellular uptake was found roughly 2-fold lower. Conversely, [Au(tu)(PEt₃)] [Cl] seemed to hardly
28
29 cross cellular plasmalemma giving rise to a cellular gold amount of about 4 times lower compared with the
30
31 reference gold(I) compound. Clearly, the degree of uptake of all gold(I) derivatives correlates well with the
32
33 cytotoxicity data.
34
35
36
37
38
39
40
41

42 **3.6. ROS production** 43 44 45 46

47 It is well-known that mitochondria can generate hydrogen peroxide [33] and, thus, play a crucial role in the
48
49 apoptotic process [34]. Moreover, it has been previously shown that TrxR inhibition alters cell conditions, as the
50
51 increase of hydrogen peroxide concentration due to the prevention of its removal causes an imbalance in cell
52
53 redox conditions, thus leading to mitochondrial membrane permeabilization and swelling [35,36]. On this basis,
54
55 we thought it of interest to measure the modification of H₂O₂ basal production in 2008 cancer cells treated with
56
57 IC₅₀ concentrations of gold(I) complexes by using the peroxide-sensitive fluorescent probe CM-DCFDA (Fig.
58
59
60 4). Antimycin, a classic inhibitor of the mitochondrial respiratory chain at the level of complex III, used as a
61
62
63
64
65

1 positive control, was able to stimulate the production of hydrogen peroxide. All the compounds were able to
2
3 increase the hydrogen peroxide basal production at a level similar ($[\text{AuBr}(\text{PEt}_3)]$, $[\text{Au}(\text{tu})(\text{PEt}_3)][\text{Cl}]$,
4
5 $[\text{Au}(\text{dedc})(\text{PEt}_3)]$) or higher ($[\text{Au}(\text{CN})(\text{PEt}_3)]$, $[\text{Au}(\text{SCN})(\text{PEt}_3)]$, $[\text{AuCl}(\text{PEt}_3)]$ and $[\text{Au}(\text{xant})(\text{PEt}_3)]$) than that
6
7 elicited by antimycin.
8
9

10 11 12 13 **3.7. Apoptosis and cell cycle studies** 14

15
16
17
18 It has been previously reported that auranofin and other gold(I) derivatives induce apoptosis in cancer cells
19
20 through the activation of caspases [37,38]. As caspase-3 is a well-known executor enzyme in apoptosis pathway
21
22 [39], we have investigated the ability of gold(I) derivatives to activate caspase-3 in 2008 cells treated for 12 h
23
24 with IC_{50} concentrations of these compounds. Fig. 5 A shows that all derivatives markedly stimulated caspase-3
25
26 activity with respect to the control. The most active compounds were the gold(I) complexes bearing the cyanate,
27
28 thiocyanate and xanthogenate ligands, with an apoptosis induction about 1.2, 1.4 and 1.6 times greater with
29
30 respect to that induced by auranofin treatment, respectively. On the contrary, $[\text{Au}(\text{tu})(\text{PEt}_3)][\text{Cl}]$ was the less
31
32 effective, with a caspase-3 activation roughly 2 times lower compared to that exerted by auranofin.
33
34
35
36
37
38
39

40 Nuclear DNA fragmentation and apoptosome complex formation are critical steps in the apoptotic process
41
42 [40]. DNA fragmentation tests performed on 2008 cells treated for 24 h with IC_{50} concentrations showed the
43
44 ability of all gold(I) derivatives to increase mono- and oligo-nucleosome formation, although to a different
45
46 extent (Fig. 5 B). In particular, $[\text{Au}(\text{xant})(\text{PEt}_3)]$ appeared the most efficient in inducing DNA fragmentation,
47
48 being able to increase about three times nucleosome formation. $[\text{Au}(\text{tu})(\text{PEt}_3)][\text{Cl}]$ and $[\text{AuCl}(\text{PEt}_3)]$ were the
49
50 less effective, with a DNA fragmentation about 3 and 10 times lower compared to that exerted by auranofin,
51
52 respectively.
53
54
55
56

57 Figure 5 C shows Hoechst33342 and DAPI stained 2008 cells after 24 h treatment with IC_{50} concentrations
58
59 of $[\text{Au}(\text{xant})(\text{PEt}_3)]$. Treated cells as compared with untreated cells, displayed chromatin condensation and
60
61 fragmentation characteristics, typical features of apoptosis.
62
63

1
2
3 Apoptotic cell death induction was confirmed through a time dependent cell cycle analysis performed by
4
5
6 FACS. Fig. 6 reports cell cycle profiles of 2008 cells treated for 24 h with IC₅₀ concentrations of
7
8 [Au(CN)(PEt₃)], [Au(SCN)(PEt₃)] and [Au(xant)(PEt₃)] that distinguished themselves as the most effective
9
10 compounds, being able to increase sub-G1 cell population of about 6, 11 and 14 times with respect to control
11
12 cells. However, a slight accumulation of 2008 cells in G2/M phase was observed after treatment with all tested
13
14 gold(I) complexes.
15
16

20 4. Discussion

25 The Trx system, which includes NADPH, thioredoxin reductase (TrxR), and Trx, participates in several cell
26
27 processes including reduction of protein disulfides, removal of hydrogen peroxide through peroxiredoxins,
28
29 formation of deoxyribonucleotides mediated by ribonucleotide reductase, and regulation of transcription factors
30
31 [41]. TrxR has recently emerged as a new exciting anti-cancer target since it is overexpressed in various
32
33 aggressive tumors and may contribute to drug resistance. Indeed, expression level of TrxR correlates well with
34
35 the resistance of several human tumor cells to cisplatin, doxorubicin, adriamycin and other chemotherapeutics
36
37 [42,43]. TrxR is endowed with a flexible C-terminal extension containing a cysteine/selenocysteine redox center
38
39 [44] that can easily interact with different and chemically unrelated substrates and inhibitors. Most of the
40
41 recognized inhibitors of thioredoxin reductase are electrophilic compounds interacting at the level of the SH/Se⁻
42
43 motif of the C-terminal portion of the enzyme [45]. Previous research has shown that gold(I) compounds readily
44
45 react with physiological thiols forming relatively stable thiol gold(I) adducts [46]. However, the various cellular
46
47 thiols exhibit a different reactivity depending on steric factors and, primarily, on their acidity, as apparent from
48
49 the pH dependency [47]. Consequently, to explain the reactivity and cellular distribution of triethylphosphine
50
51 gold(I) compounds, a sequential thiol exchange mechanism has been proposed [48]. According to this
52
53 mechanism, membrane sulfhydryl groups exert a shuttling action of the gold-triethylphosphine moiety to the
54
55 cytosolic sulfhydryl groups. Thiolates are known to act as 'soft' ligands forming covalent bonds with the 'soft'
56
57

1 gold(I) ion; corresponding selenolates are 'softer' donor ligands compared to thiolates and, consequently,
2
3 behave as better substrates for the gold(I) ion [49-51]. This enhanced affinity of the gold(I) ion for selenolates
4
5 makes the selenocysteine group present in a well accessible C-terminal arm of thioredoxin reductase, a primary
6
7 selective target of gold (I) compounds. Gold(I) complexes are linear complexes characterized by a mono-
8
9 cationic gold ion coordinated by two ligands (usually a neutral along with a mononegative ligand).
10
11

12
13
14
15 In our $[\text{Au}(\text{X})(\text{PEt}_3)]$ -type complexes, the triethylphosphine ligand was retained for all the compounds, as
16
17 $[\text{Au}(\text{PEt}_3)]^+$ moiety has been found critical to achieve a significant *in vitro* antitumor activity [12]. The (X)
18
19 group was selected (Scheme 1) among a series of ligands possessing different binding strength to gold in order
20
21 to investigate a possible structure-activity relationship based on the different lability of the Au-(X) bond. In fact,
22
23 the lability of the thiolate group may play a crucial role in the biodistribution and kinetic properties of this class
24
25 of metal complexes. Consequently, a different degree of reactivity with both physiological thiolates and/or
26
27 selenolate groups could be envisaged depending on the various (X) ligands utilized. In order to correlate the
28
29 influence of the variable ligands (X) in our compounds to the different effects observed we may tentatively refer
30
31 to the softness-hardness principle [52]. The latter suggests that hard acids preferentially associate with hard
32
33 bases, while soft acids prefer to combine with soft bases. The halogens Cl and Br are a hard base and a
34
35 borderline hard/soft base, respectively and consequently show scarce preference for the soft acid Au(I). As
36
37 matter of fact $[\text{AuCl}(\text{PEt}_3)]$ and $[\text{AuBr}(\text{PEt}_3)]$ derivatives are the less active both in inhibiting thioredoxin
38
39 reductases (Table 5) and in penetrating into the cell (Fig. 5). All the other ligands are soft bases, which exhibit
40
41 high preference for the gold(I) center, although to a different extent. In particular, the binding of
42
43 dithiocarbamate and xanthogenate ligands to gold is strengthened by the mesomeric resonance form. The gold
44
45 compounds bearing these ligands ($[\text{Au}(\text{dedc})(\text{PEt}_3)]$ and $[\text{Au}(\text{xant})(\text{PEt}_3)]$) are particularly effective both in
46
47 inhibiting thioredoxin reductases (Table 5) and in penetrating through cell membranes (Fig. 3). Possibly, these
48
49 complexes can easily reach the biological target and once there exchange their ligands with the cellular
50
51 nucleophiles either when entering the cell or when interacting with the selenolate or thiolate groups present at
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 the active site of thioredoxin reductases. However, also other properties of the ligands, including steric and
2
3 electronic properties and lipophilicity contribute to the different effects observed.
4

5
6
7
8 Thiol redox state and cellular hydrogen peroxide levels are controlled not only by thioredoxin system but
9
10 also by glutathione system which depends on glutathione reductase. Both systems utilize NADPH and remove
11
12 hydrogen peroxide through the respective peroxidases. Glutathione peroxidase and thioredoxin reductase
13
14 possess a selenol group at their catalytic site. It has been already described that some phosphine gold(I)
15
16 compounds are also able to inhibit glutathione peroxidase at very low concentrations [37]. *In vitro* studies on the
17
18 interaction with TrxR, GR and GPx showed that all phosphine gold complexes, as already stated for a variety of
19
20 gold compounds, mostly inhibit cytosolic and mitochondrial TrxR enzyme isoforms while GR and GPx required
21
22 higher concentrations to be inhibited. In this context, previous studies established that the rate of enzyme
23
24 inhibition may depend either on the structure of the active site or on the lability of the gold-ligand bond [53].
25
26
27
28
29
30
31
32

33 In previous studies we have compared the cellular response of human ovarian cancer cells to auranofin with
34
35 that evoked by cisplatin, the first line drug against ovarian cancer [9]. Auranofin, acting as a potent TrxR
36
37 inhibitor, determined an alteration of the cellular redox state leading to an oxidation of the components of the
38
39 Trx system thus triggering apoptosis [54]. In human ovarian cancer cells phosphine gold(I) derivatives markedly
40
41 inhibited TrxR and, to a lesser extent also GR and GPx. Moreover, the cationic complex, $[\text{Au}(\text{tu})(\text{PEt}_3)][\text{Cl}]$,
42
43 appeared less effective in inhibiting enzyme activity confirming its reduced bioactivity observed in cytotoxicity
44
45 as well in apoptosis induction experiments. This behaviour could be related to the charged nature of this species
46
47 that may hinder its ability to cross the cell membrane by passive diffusion. ICP measurements of cellular gold
48
49 accumulation (Fig. 3) are consistent with this hypothesis. Furthermore, uptake experiments gave important
50
51 information concerning the essential role of the (X) ligand in facilitating cellular internalization. In fact, gold(I)
52
53 complexes bearing the most lipophilic xant and dedc ligands, as well as those complexes involving a metal-X
54
55 covalent bond (complexes **3-6** and **8**) entered cells roughly 2 times more efficiently than the halogenated gold
56
57 compounds (complexes **1** and **2**), that are characterised by a partial ionic interaction between the metal and
58
59
60
61
62
63
64
65

1 halogen. In conclusion, neutral and lipophilic gold(I) compounds are internalised more efficiently than charged
2
3 gold(I) compounds. Coherently, cytotoxicity studies highlighted neutral $[\text{Au}(\text{xant})(\text{PEt}_3)]$, $[\text{Au}(\text{CN})(\text{PEt}_3)]$ and
4
5 $[\text{Au}(\text{SCN})(\text{PEt}_3)]$ as the most powerful derivatives. In a parallel study, by considering the cytotoxic profiles of a
6
7 series of linear alkylphosphine and arylphosphine gold(I) dithiocarbamate and xanthate compounds, de Vos *et*
8
9 *al.* demonstrated that they possess a greater cytotoxicity than cisplatin, xanthate derivatives being less active
10
11 than dithiocarbamate ones [11]. Similarly, our tested xant and dedc complexes showed a significant cytotoxic
12
13 efficiency, although the xanthate derivative was found to be more efficient than the dithiocarbamate counterpart.
14
15 In this field, other studies [55] indicated that xanthate complexes of several metals, including gold, palladium
16
17 and bismuth, are endowed with a high antitumor activity. It has also to be considered that xanthate ligands are
18
19 reported to be, in general, less toxic than dithiocarbamate ligands [11]. Interestingly, some members of the
20
21 xanthate family such as tricyclododecan-9-yl-xanthogenate showed selective cytotoxicity towards tumor cells
22
23 and favor apoptosis by inhibiting sphingosine kinase [56]. Our studies have demonstrated that $[\text{Au}(\text{xant})(\text{PEt}_3)]$
24
25 strongly decreased cancer cell viability inducing a massive apoptosis. The marked inhibition of TrxR leads to
26
27 the generation of superoxide anion radicals, resulting in an accumulation of intracellular ROS that triggers
28
29 apoptosis. Moreover, the TrxR inhibition impairs the control of apoptosis signal-regulating kinase 1 (ASK-1)
30
31 activity exerted by Trx, resulting in the activation of downstream signaling cascades such as MAP kinase
32
33 apoptotic cell death pathway [57]. In order to characterize the cell death program triggered by tested gold(I)
34
35 compounds and to correlate TrxR inhibition to apoptosis induction, we have examined some characteristic
36
37 events of apoptosis in ovarian cancer cells. A close relationships between TrxR inhibition and apoptosis
38
39 induction has been highlighted with $[\text{Au}(\text{SCN})(\text{PEt}_3)]$ and $[\text{Au}(\text{CN})(\text{PEt}_3)]$. Thiocyanate is a physiological
40
41 ligand having a “soft” character suitable for interaction with gold(I) ions. Serum thiocyanate concentrations are
42
43 relatively high (from 10 to 100 μM) and increase to the millimolar range in milk, saliva and tears [58,59].
44
45 Thiocyanate present in the body fluids derives from dietary sources and from the cyanide detoxification reaction
46
47 involving thiosulfate and catalyzed by rhodanese. Its affinity for gold(I) would also depend on the presence of
48
49 two isomeric forms, as described in the case of $[\text{Au}(\text{SCN})(\text{PMe}_3)]$ and $[\text{Au}(\text{NCS})(\text{PMe}_3)]$ contributing to the
50
51 formation of the complex [60]. Our results showed that $[\text{Au}(\text{SCN})(\text{PEt}_3)]$ elicited marked cytotoxic properties,
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 strong inhibitory effects on thioredoxin reductase and also make the cells more prone to apoptosis.

2
3 [Au(SCN)(PEt₃)] provides a molecule where the small NCS⁻ ligand can be easily displaced by the S⁻/Se⁻ group
4
5
6 of thioredoxin reductase, thus explaining the above reported properties.

7
8 Recent studies focused on bis-chelate Au(I) complexes of the ligand 1,3-bis(di-2-pyridylphosphino)propane
9
10 [38], Au(I) N-heterocyclic carbenes [61] and phosphine Au(I) naphthalimide [62] show that these compounds
11
12 exhibit selective cytotoxicity towards cancer cells consequent to an efficient inhibition of thioredoxin reductase.
13
14 In the first study [40] the pyridylphosphino ethane complexes show a low reactivity with protein thiols, while
15
16 the corresponding analogs containing pyridylphosphino propane ligands show a great tendency to stimulate
17
18 ligand exchange reactions with thiols indicating that a six-membered chelate ring undergo a more facile ring
19
20 opening compared to the corresponding five-membered chelates. The peculiar role of phosphine and carbene
21
22 ligands in gold(I) pro-drugs appears to be under the control of the chemical reactivity of the gold centre [38,61-
23
24 63]. Moreover, other properties of the ligands such as size, charge, lipophilicity and toxicity determine their
25
26 biological activity and biodistribution. Finally, in order to be efficient in the biological context, gold(I)
27
28 complexes should be relatively stable to reach their specific molecular targets, but not too stable to hamper the
29
30 reaction with the target itself. In linear gold(I) complexes, these properties are permitted and tuned by the
31
32 accurate choice of the ligands and some of the ligands used in the present work, such as thiocyanate and
33
34 xanthate, offer interesting perspectives for further studies. In conclusion, these findings clearly validate further
35
36 investigations for the customization of TrxR inhibition induced by gold(I) complexes with a view to obtain
37
38 increasingly effective therapeutics able to overcome drug resistance afforded by TrxR overexpression.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Acknowledgments

This work was financially supported by University of Padova (Progetto di Ateneo CPDA065113/06), Ministero dell'Istruzione dell'Università e della Ricerca (PRIN 20078EWK9B) and Swedish Cancer Society (Cancerfonden).

1 **Figure captions**

2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure 1. Reaction pathways for the preparation of gold(I) complexes.

Legend: *i*) Ag NO₃; *ii*) NaBr; *iii*) KCN; *iv*) KSCN; *v*) Nadedc; *vi*) Kxant, Na₂S₂O₃;

vii) tu.

Figure 2. Effects of gold(I) complexes on redox enzymes in human ovarian cancer cells. 2008 cells were

incubated for 18 h with IC₅₀ of tested compounds. Subsequently, cells were washed twice with PBS and lysed.

Thioredoxin reductase activity was assayed by measuring NADPH- dependent reduction of DTNB at 412 nm

(A); glutathione reductase activity (B) and glutathione peroxidase (C) activities were followed at 340 nm.

Figure 3. Estimation of gold(I) compound uptake in 2008 cells. 2008 cells were incubated for 18 h with IC₅₀

of tested compounds. Au cellular content was estimated by means of ICP analysis. Results are expressed as ng

Au/mg of proteins.

Figure 4. Effect of gold(I) compounds on hydrogen peroxide formation in 2008 cells. 2008 cells were pre-

incubated in PBS/10 mM glucose medium for 20 min at 37°C in presence of 10 μM CM-DCFDA and then

treated with IC₅₀ of gold(I) compounds. Control cells: dashed line. Gold(I) complexes treated cells: continuous

line. Antimycin treated cells: dotted line.

Figure 5. Effect of gold(I) compounds on caspase-3 activation (A), nucleosome formation (B) DAPI and

Hoechst staining (C). 2008 cells were incubated for 12 h with IC₅₀ of gold(I) compounds and then submitted to

the test on caspase-3 induction (A). For DNA fragmentation experiments (B) and DAPI and Hoechst staining

(C), 2008 cells were incubated for 24 h in presence of IC₅₀ of gold(I) compounds.

1 **Figure 6. Cell cycle analysis of 2008 cells treated with gold(I) compounds.** 2008 cells were treated with
2
3 gold(I) derivatives for 24 h. Cell cycle profiles were analyzed by flow cytometry after DNA staining with
4
5 propidium iodide.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Accepted Manuscript

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65**References**

1. Gordon DA. In: Kelley WN, Harris ED, Ruddy S, Sledge SB, editors. Textbook of Rheumatology (IV ed.), Philadelphia, WB Saunders company 1989. p. 805-23.
2. Shaw CF III. Gold-based therapeutic agents. Chem Rev 1999;99:2589-2600.
3. Hill DD, Sutton BM. (2,3,4,6-tetra-O-acetyl-1-D-thiopyranosato-S)(triethylphosphine) gold. Cryst Struct Comm 1980;9:679-86.
4. Allen FH. The Cambridge Structural Database: a quarter of a million crystal structures and rising. Acta Crystallogr 2002 (Sect. B);58:380-8.
5. Coffey MT, Shaw CF III, Eidsness MK, Watkins JW II, Elder RC. Reactions of auranofin and chloro(triethylphosphine)gold with bovine serum albumin. Inorg Chem 1986;25:333-9.
6. Roberts J, Xiao J, Schliesman B, Parsons DJ, Shaw CF III. Kinetics and Mechanism of the Reaction between Serum Albumin and Auranofin (and Its Isopropyl Analogue) in Vitro. Inorg Chem, 1996;35:424-433.
7. Christodoulou J, Sadler PJ, Tucker A. A New Structural Transition of Serum Albumin Dependent on the State of Cys34. Detection by $^1\text{H-NMR}$ Spectroscopy. Eur J Biochem 1994;225:363-8.
8. Berners-Price SJ, Johnson RK, Mirabelli CK, Faucette LF, McCabe FL, Sadler PJ. Copper(I) complexes with bidentate tertiary phosphine ligands: solution chemistry and antitumor activity. Inorg Chem 1987;26:3383-7.
9. Marzano C, Gandin V, Folda A, Scutari G, Bindoli A, Rigobello MP. Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radical Biol Med 2007;42:872-81.
10. Talib J, Beck JL, Ralph SF. A mass spectrometric investigation of the binding of gold antiarthritic agents and the metabolite $[\text{Au}(\text{CN})_2]^{(-)}$ to human serum albumin. J Biol Inorg Chem 2006;11:559-70.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
11. de Vos D, Ho SY, Tiekink ERT. Cytotoxicity profiles for a series of triorganophosphinegold(I) dithiocarbamates and triorganophosphinegold(I) xanthates. *Bioinorg Chem Appl* 2004;2:141-54.
 12. Tiekink ERT. Phosphinegold(I) thiolates-pharmacological use and potential. *Bioinorg Chem Appl* 2003;1:3-67.
 13. Ronconi L, Marzano C, Zanello P, Corsini M, Miolo G, Maccà C et al. Gold(III) dithiocarbamate derivatives for the treatment of cancer: solution chemistry, DNA binding, and hemolytic properties. *J Med Chem* 2006;49:1648-57.
 14. El-Etri MM, Scovell WM. Synthesis and spectroscopic characterization of (triethylphosphine)gold(I) complexes $AuX(PEt_3)$ ($X = Cl, Br, CN, SCN$), $[AuL(PEt_3)^+]$ ($L = SMe_2, SC(NH_2)_2, H_2O$), and $(\mu-S)[Au(PEt_3)]_2$. *Inorg Chem* 1990;29:480-4.
 15. Coates GE, Kowala C, Swan JM. Coordination compounds of group 1B metals I, triethylphosphine complexes of gold(I) mercaptides. *Aust J Chem* 1966;19:539-45.
 16. Sutton BM, McGusty E, Waltz DT, Di Martino MJ. Oral gold. Antiarthritic properties of alkylphosphinegold coordination complexes. *J Med Chem* 1972;15:1095-8.
 17. Björkhem-Bergman L, Jönsson K, Eriksson LC, Olsson JM, Lehmann S, Paul C, Björnstedt M. Drug-resistant human lung cancer cells are more sensitive to selenium cytotoxicity. Effects on thioredoxin reductase and glutathione reductase. *Biochem Pharmacol* 2002;63:1875-84.
 18. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. *Cancer Res* 1988;48:589-601.
 19. Lowry OH, Rosebrough NJ, Farr AL, Randall R. Protein measurement with the Folin phenol reagent. *J Biol Chem* 1951;193:265-75.
 20. Luthman M, Holmgren A. Rat liver thioredoxin and thioredoxin reductase: Purification and characterization. *Biochemistry* 1982;21:6628-33.

- 1 21. Rigobello MP, Callegaro MT, Barzon E, Benetti M, Bindoli A. Purification of mitochondrial
2
3 thioredoxin reductase and its involvement in the redox regulation of membrane permeability. Free
4
5 Radic Biol Med 1998;24:370-6.
6
7
- 8 22. Little C, Olinescu R, Reid KG, O'Brien PJ. Properties and regulation of glutathione peroxidase. J
9
10 Biol Chem 1970;245:3632-6.
11
12
- 13 23. Nicoletti I, Migliorati G, Pagliacci MC. A rapid and simple method for measuring thymocyte
14
15 apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139:271-9.
16
17
- 18 24. Hill DT, Sutton BM. (2,3,4,6-tetra-O-acetyl- β -1-D-thiopyranosato-S)(triethylphosphine)gold. Cryst
19
20 Struct Comm 1980;9:679-86.
21
22
- 23 25. Ho SY, Tiekink ERT. Crystal structure of (diethyldithiocarbamate) (triethylphosphine) gold(I). Z
24
25 Krystallogr NCS 2005;220:342-4.
26
27
- 28 26. Hormann AL, Shaw CF III, Bennett DW, Reiff WM. Solid-state structure and solution equilibria of
29
30 cyano(triethylphosphine)gold(I). Inorg Chem 1986;25:3953-57.
31
32
- 33 27. Mamenta EL, Poma EE, Kaufmann WK, Delmastro DA, Grady HL, Chaney SG. Enhanced
34
35 replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell
36
37 lines. Cancer Res 1994;54:3500-5.
38
39
- 40 28. Lanzi C, Perego P, Supino R, Romanelli S, Pensa T, Carenini N et al. Decreased drug accumulation
41
42 and increased tolerance to DNA damage in tumor cells with a low level of cisplatin resistance.
43
44 Biochem Pharmacol 1998;55:1247-54.
45
46
- 47 29. Zinkewich-Peotti K, Andrews PA. Loss of cis-diamminedichloroplatinum(II) resistance in human
48
49 ovarian carcinoma cells selected for rhodamine 123 resistance. Cancer Res 1992;52:1902-6.
50
51
- 52 30. Jönsson-Videsäter K, Andersson G, Bergh J, Paul C. Doxorubicin-resistant, MRP1-expressing U-
53
54 1285 cells are sensitive to idarubicin. Ther Drug Monit 2003;25:331-9.
55
56
- 57 31. Wersinger C, Rebel G, Lelong-Rebel IH. Detailed study of the different taurine uptake systems of
58
59 colon LoVo MDR and non-MDR cell lines. Amino Acids 2000;19:667-85.
60
61
62
63
64
65

- 1 32. Sun Q-A, Wu Y, Zappacosta F, Jeang K-T, Lee BJ, Hatfield DL et al. Redox regulation of cell
2 signaling by selenocysteine in mammalian thioredoxin reductases. *J Biol Chem* 1999;274:24530-52.
3
4
5
6 33. Loschen G, Flohé L, Chance B. Respiratory chain linked H₂O₂ production in pigeon heart
7 mitochondria. *FEBS Lett* 1971;18:261-4.
8
9
10
11 34. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. *Nature* 2000;408:239-
12 47.
13
14
15
16 35. Rigobello MP, Scutari G, Folda A, Bindoli A. Mitochondrial thioredoxin reductase inhibition by
17 gold(I) compounds and concurrent stimulation of permeability transition and release of cytochrome c.
18 *Biochem Pharmacol* 2004;67:689-96.
19
20
21
22
23 36. Rigobello MP, Scutari G, Boscolo R, Bindoli A. Induction of mitochondrial permeability transition
24 by auranofin, a gold(I)-phosphine derivative. *Br J Pharmacol* 2002;136:1162-8.
25
26
27
28 37. Rigobello MP, Folda A, Dani B, Menabò R, Scutari G, Bindoli A. Gold(I) complexes determine
29 apoptosis with limited oxidative stress in Jurkat T cells. *Eur J Pharmacol* 2008;582:26-34.
30
31
32
33 38. Rackham O, Nichols SJ, Leedman PJ, Berners-Price SJ, Filipovska A. A gold(I) phosphine complex
34 selectively induces apoptosis in breast cancer cells: implications for anticancer therapeutics targeted
35 to mitochondria. *Biochem Pharmacol* 2007;74:992-1002.
36
37
38
39
40 39. Zakeri Z, Lockshin RA. Cell death: history and future. *Adv Exp Med Biol* 2008;615:1-11.
41
42
43 40. Riedl SJ, Salvesen GS. The apoptosome: signalling platform of cell death. *Nat Rev Mol Cell Biol*
44 2007;8:405-13.
45
46
47
48 41. Powis G, Montfort WR. Properties and biological activities of thioredoxins. *Annu Rev Pharmacol*
49 *Toxicol* 2001;41:261-95.
50
51
52 42. Wang J, Kobayashi M, Sakurada K, Imamura M, Moriuchi T, Hosokawa M. Possible roles of an adult
53 T-cell leukemia (ATL)-derived factor/thioredoxin in the drug resistance of ATL to Adriamycin.
54 *Blood* 1997;89:2480-7.
55
56
57
58
59
60
61
62
63
64
65

- 1 43. Yokomizo A, Ono M, Nanri H, Makino Y, Ohga T, Wada M et al. Cellular levels of thioredoxin
2 associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. *Cancer Res*
3 1995;55:4293–6.
4
5
6
7
8 44. Nishinaka Y, Nakamura H, Masutani H, Yodoi J. Redox control of cellular function by thioredoxin:
9 A new therapeutic direction in host defense. *Arch Immunol Ther Exp* 2001;49: 285-92.
10
11
12 45. Nordberg J, Arnér ESJ. Reactive oxygen species, antioxidants, and the mammalian thioredoxin
13 system. *Free Radic Biol Med* 2001;31:1287-1312.
14
15
16
17 46. Sadler PJ, Guo Z. Metal complexes in medicine: design and mechanism of action. *Pure Appl Chem*
18 1998;7:863-71.
19
20
21
22 47. Christodoulou J, Sadler PJ, Tucker A. ¹H NMR of albumin in human blood plasma: drug binding and
23 redox reaction at Cys34. *FEBS Lett* 1995;376:1-5.
24
25
26
27 48. Snyder RM, Mirabelli CK, Crooke ST. Cellular association, intracellular distribution, and efflux of
28 auranofin via sequential ligand exchange reactions. *Biochem Pharm* 1986;35:923-32.
29
30
31
32 49. Chaudière J, Tappel AL. Interaction of gold(I) with the active site of selenium-glutathione
33 peroxidase. *J Inorg Biochem* 1984;20:313-25.
34
35
36
37 50. Roberts JR, Shaw CF III. Inhibition of erythrocyte selenium-glutathione peroxidase by auranofin
38 analogues and metabolites. *Biochem Pharmacol* 1998;55:1291-9.
39
40
41
42 51. Sadler PJ. The comparative evaluation of the physical and chemical properties of gold compounds. *J*
43 *Rheumatol Suppl* 1982;8:71-8.
44
45
46
47 52. Pearson RG., *Acids and Base. Science* 1966;151:151-177.
48
49
50 53. Lee MT, Ahmed T, Haddad R, Friedman ME. Inhibition of several enzymes by gold compounds. II.
51 beta-Glucuronidase, acid phosphatase and L-malate dehydrogenase by sodium thiomalatoaurate (I),
52 sodium thiosulfatoaurate (I) and thioglucosaurate (I). *J Enzyme Inhib* 1989;3:35-47.
53
54
55
56 54. Rigobello MP, Gandin V, Folda A, Rundlöf AK, Fernandes AP, Bindoli A, Marzano C, Björnstedt
57 M. Treatment of human cancer cells with selenite or tellurite in combination with auranofin enhances
58
59
60
61
62
63
64
65

- 1 cell death due to redox shift. Free Rad Biol Med 2009, Accepted manuscript,
2
3 doi:10.1016/j.freeradbiomed.2009.05.027.
4
5
- 6 **55.** Friebolin W, Schilling G, Zöller M, Amtmann E. Antitumoral activity of non-platinum xanthate
7
8 complexes. J Med Chem 2005;48:7925-31.
9
- 10 **56.** Meng A, Luberto C, Meier P, Bai A, Yang X, Hannun YA et al. Sphingomyelin synthase as a
11
12 potential target for D609-induced apoptosis in U937 human monocytic leukemia cells. Exp Cell Res
13
14 2004;292:385-92.
15
16
17
- 18 **57.** Park SJ, Kim IS. The role of p38 MAPK activation in auranofin-induced apoptosis of human
19
20 promyelocytic leukaemia HL-60 cells. Br J Pharmacol 2005;146:506-13.
21
22
- 23 **58.** Thomas, E. L. In: Pruitt KM, Tenovou JO editors. The Lactoperoxidase System, Chemistry and
24
25 Biological Significance, Marcel Dekker, New York, 1985, p 31-53.
26
27
- 28 **59.** Arlandson M, Decker T, Roongta VA, Bonilla L, Mayo KH, MacPherson JC et al. Eosinophil
29
30 peroxidase oxidation of thiocyanate. J Biol Chem 2001;276:215-24.
31
32
- 33 **60.** Berger RJF, Patzschke M, Schneider D, Schmidbaur H, Sundholm D. Isomeric mono- and
34
35 bis[(phosphane)gold(I)] thiocyanate complexes. Chem Eur J 2005;11:3574-82.
36
37
- 38 **61.** Hickey JL, Ruhayel RA, Barnard PJ, Baker MV, Berners-Price SJ, Filipovska A. Mitochondria-
39
40 targeted chemotherapeutics: the rational design of gold(I) N-heterocyclic carbene complexes that are
41
42 selectively toxic to cancer cells and target protein selenols in preference to thiols. J Am Chem Soc
43
44 2008;130:12570-1.
45
46
- 47 **62.** Ott I, Qian X, Xu Y, Vlecken DHW, Marques IJ, Kubutat D et al. A gold(I) phosphine complex
48
49 containing a naphthalimide ligand functions as a TrxR inhibiting antiproliferative agent and
50
51 angiogenesis inhibitor. J Med Chem 2009;52:763-70.
52
53
- 54 **63.** Barnard PJ, Berners-Price SJ. Targeting the mitochondrial cell death pathway with gold compounds.
55
56 Coord Chem Rev 2007;251:1889-1902.
57
58
59
60
61
62
63
64
65

Accepted Manuscript

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Table 1. Physico-chemical data of phosphine gold(I) complexes utilised in this study.

Gold(I) complex	$^{31}\text{P}^a$	$\text{Et}_3\text{P}\text{-----Au}\text{-----}(\text{X})^b$		$\text{P}\text{--Au--X}^c$
PEt_3	-17.80			
$[\text{AuCl}(\text{PEt}_3)]$ (1)	32.32	2.306 (Cl)	178.7
$[\text{AuBr}(\text{PEt}_3)]$ (2)	35.18			
$[\text{Au}(\text{CN})(\text{PEt}_3)]$ (3)	36.81	2.288	1.971 (C)	176.6
$[\text{Au}(\text{SCN})(\text{PEt}_3)]$ (4)	37.23			
$[\text{Au}(\text{dedc})(\text{PEt}_3)]$ (5)	34.76	2.245	2.337 (S)	173.8
$[\text{Au}(\text{xant})(\text{PEt}_3)]$ (6)	36.65	2.265	2.328 (S)	177.7
$[\text{Au}(\text{tu})(\text{PEt}_3)][\text{Cl}]^c$ (7)	36.31			
$[\text{Au}(\text{S-thiog})(\text{PEt}_3)]$ (8) 'auranofin'	38.06	2.259	2.293 (S)	173.6

^a Unless otherwise specified, NMR spectra are recorded in chloroform-*d*.

^b Au-P and Au-X distances in Å.

^c P-Au-X angle in degree (°).

^d NMR spectra recorded in dimethylsulfoxide-*d*₆.

Table 2. Cytotoxicity of gold(I) complexes

Compound		IC ₅₀ (μM) ± S.D.					
		HL60	A549	MCF-7	A375	HCT-15	HeLa
[AuCl(PEt ₃)]	(1)	0.52±0.13	0.85±0.01	0.84±0.01	0.78±0.31	0.97±0.17	0.90±0.21
[AuBr(PEt ₃)]	(2)	0.62±0.06	1.21±0.54	1.44±0.41	1.02±1.00	1.08±0.82	0.63±0.32
[Au(CN)(PEt ₃)]	(3)	0.19±0.07	0.41±0.06	0.45±0.12	0.21±0.23	0.08±0.01	0.09±0.02
[Au(SCN)(PEt ₃)]	(4)	0.21±0.12	0.71±0.02	0.65±0.11	0.37±0.29	0.32±0.02	0.18±0.01
[Au(dedc)(PEt ₃)]	(5)	0.96±1.21	1.22±0.96	1.63±0.58	1.47±0.77	0.92±0.01	0.54±0.07
[Au(xant)(PEt ₃)]	(6)	0.19±0.06	0.33±0.47	0.41±0.21	0.13±0.27	0.61±0.13	0.13±0.61
[Au(tu)(PEt ₃)] [Cl]	(7)	2.84±1.29	3.01±1.01	3.28±1.12	2.23±1.03	2.75±1.43	1.84±0.25
Auranofin	(8)	0.23±0.11	0.75±0.05	0.98±0.32	0.34±0.21	0.11±0.02	0.15±0.03
Cisplatin		4.56±1.13	29.21±1.92	19.04±1.51	2.37±1.23	20.34±1.31	8.50±1.51

S.D.= standard deviation

IC₅₀ values were calculated by probit analysis ($P < 0.05$, χ^2 test). Cells ($5-8 \cdot 10^4 \cdot \text{mL}^{-1}$) were treated for 72 h with increasing concentrations of tested compounds. Cytotoxicity was assessed by MTT test.

Table 3. Cisplatin cross-resistance profiles

Compound		Human ovarian adenocarcinoma cells			
		2008 IC ₅₀ (μM) ± S.D.	C13 IC ₅₀ (μM) ± S.D.	R.F.	RH4 IC ₅₀ (μM) ± S.D.
[AuCl(PET ₃)]	(1)	1.12±0.29	1.05±0.43	0.93	0.91±0.53
[AuBr(PET ₃)]	(2)	1.61±0.71	1.06±0.68	0.66	0.93±0.47
[Au(CN)(PET ₃)]	(3)	0.99±0.01	0.96±0.25	0.96	0.98±0.12
[Au(SCN)(PET ₃)]	(4)	0.95±0.02	0.94±0.04	0.93	0.12±0.59
[Au(dedc)(PET ₃)]	(5)	0.86±1.38	0.87±0.98	1.00	0.81±0.45
[Au(xant)(PET ₃)]	(6)	0.67±0.65	0.66±0.02	0.98	0.68±0.58
[Au(tu)(PET ₃)] [Cl]	(7)	4.21±2.30	4.13±0.74	1.08	4.09±2.11
Auranofin	(8)	1.01±0.97	0.43±0.09	0.43	0.89±0.72
Cisplatin		10.14±1.43	89.18±2.08	8.79	26.61±1.53

Compound		Human cervix carcinoma cells		
		A431 IC ₅₀ (μM) ± S.D.	A431/Pt IC ₅₀ (μM) ± S.D.	R.F.
[AuCl(PET ₃)]	(1)	0.95±0.11	1.08±0.91	1.14
[AuBr(PET ₃)]	(2)	1.75±0.002	1.77±0.61	1.10
[Au(CN)(PET ₃)]	(3)	0.97±0.17	0.98±0.13	1.01
[Au(SCN)(PET ₃)]	(4)	0.95±0.52	0.97±0.16	1.02
[Au(dedc)(PET ₃)]	(5)	2.02±0.75	2.06±0.72	1.02
[Au(xant)(PET ₃)]	(6)	0.53±0.76	0.27±1.44	0.94
[Au(tu)(PET ₃)] [Cl]	(7)	2.01±0.42	1.87±0.12	0.98
Auranofin	(8)	2.01±1.54	1.87±0.50	0.93
Cisplatin		22.06 ± 2.21	57.76 ± 3.94	2.61

S.D. = standard deviation

IC₅₀ values were calculated by probit analysis ($P < 0.05$, χ^2 test). Cells ($3\text{-}8 \cdot 10^4 \cdot \text{ml}^{-1}$) were treated for 48 hrs with increasing concentrations of tested compounds dissolved in DMSO. Cytotoxicity was assessed by MTT test.

Accepted Manuscript

Table 4. MDR cross-resistance profiles

Compound	Human small cell lung carcinoma cells		
	U1285	U1285dox	R.F.
	IC ₅₀ (μM) ± S.D.	IC ₅₀ (μM) ± S.D.	
[AuCl(PET ₃)] (1)	1.29±0.31	1.18±0.11	0.92
[AuBr(PET ₃)] (2)	1.43±0.17	1.41±0.36	0.99
[Au(CN)(PET ₃)] (3)	0.73±0.29	0.72±0.51	0.98
[Au(SCN)(PET ₃)] (4)	0.62±0.23	0.61±0.36	0.98
[Au(dedc)(Pet ₃)] (5)	2.33±1.04	2.46±0.93	1.06
[Au(xant)(Pet ₃)] (6)	0.79±1.56	0.43±1.43	0.54
[Au(tu)(PET ₃)] [Cl] (7)	6.62±1.98	6.69±1.39	1.01
Auranofin (8)	0.92±1.43	0.67±0.45	0.73
Doxorubicin	1.01 ± 0.34	87.07 ± 2.97	86.21
Compound	Human colon adenocarcinoma cells		
	LoVo	LoVo MDR	R.F.
	IC ₅₀ (μM) ± S.D.	IC ₅₀ (μM) ± S.D.	
[AuCl(PET ₃)] (1)	1.79±0.56	1.47±0.59	0.82
[AuBr(PET ₃)] (2)	1.85±0.77	1.21±0.86	0.65
[Au(CN)(PET ₃)] (3)	0.67±0.08	0.65±0.07	0.97
[Au(SCN)(PET ₃)] (4)	0.69±0.33	0.61±0.65	0.88
[Au(dedc)(Pet ₃)] (5)	1.33±1.54	1.04±1.50	0.78
[Au(xant)(Pet ₃)] (6)	0.69±1.56	0.57±1.59	0.82
[Au(tu)(PET ₃)] [Cl] (7)	6.06±1.98	6.28±1.67	1.04
Auranofin (8)	1.12±0.74	1.11±0.45	1.01
Doxorubicin	1.46± 2.30	44.89 ± 0.90	30.75

S.D. = standard deviation

IC₅₀ values were calculated by probit analysis ($P < 0.05$, χ^2 test). Cells ($3\text{-}8\cdot 10^4\cdot\text{ml}^{-1}$) were treated for 48 hrs with increasing concentrations of tested compounds. Cytotoxicity was assessed by MTT test.

Accepted Manuscript

Table 5 Inhibitory effect of gold(I) compounds on rat cytosolic (TrxR1) and mitochondrial (TrxR2) thioredoxin reductases, on glutathione reductase (GR) and glutathione peroxidase (GPx).

Compound		TrxR1		TrxR2		GR		GPx	
		IC ₅₀ (nM)		IC ₅₀ (nM)		IC ₅₀ (μM)		IC ₅₀ (μM)	
[AuCl(PET ₃)]	(1)	1.80±0.60	9.00±0.34	19.00±0.79	79.00±3.00				
[AuBr(PET ₃)]	(2)	1.50±0.20	7.00±0.30	17.29±0.67	89.00±4.00				
[Au(CN)(PET ₃)]	(3)	1.10±0.20	5.00±0.23	77.88±1.40	80.00±3.00				
[Au(SCN)(PET ₃)]	(4)	1.80±0.23	7.80±0.29	7.86±0.34	72.00±2.60				
[Au(dedc)(Pet ₃)]	(5)	0.31±0.45	0.70±0.32	28.01±0.45	68.00±2.45				
[Au(xant)(Pet ₃)]	(6)	0.72±0.50	3.60±1.20	18.10±1.00	40.27±2.00				
[Au(tu)(PET ₃)] [Cl]	(7)	1.00±0.30	10.00±0.42	50.37±0.98	17.53±1.34				
Auranofin	(8)	0.80±0.24	3.70±0.24	30.00±1.00	63.00±2.00				

S.D. = standard deviation

Thioredoxin reductase activity was assayed by measuring NADPH- dependent reduction of DTNB at 412 nm; glutathione reductase activity and glutathione peroxidase activities were followed at 340 nm. IC₅₀ values were calculated by probit analysis ($P < 0.05$, χ^2 test).

Accepted Manuscript

Figure 1




Figure 2.





Figure 3.



Accepted

Figure 4.




Figure 5.




Figure 5





Figure 6.



Graphical abstract

